【摘要】 为探讨应用哈乐治疗前列腺增生症（BPH）的临床疗效、安全性、临床适应症及更有效的用药方法,分别应用日服哈乐0.2mg、0.4mg治疗前列腺增生症各30例,并用高特灵2mg作对照。结果表明,哈乐和高特灵对减轻BPH患者的临床症状、增加尿流率,减少残余尿及改善病人的生活质量安全有效。哈乐与高特灵的临床疗效无显著差异,而副作用发生率明显低于高特灵,尤其是心血管方面的不良反应。日服哈乐0.4mg较0.2mg改善症状更快速有效,并不明显增加其副作用,故对症状明显者可选用。认为哈乐是目前治疗BHP较理想的高选择性α_1A-AR阻滞剂。更多还原

【Abstract】 To evaluate the efficacy, safety, indications and usage of tamsuiosin, 30 patients with symptomatic benign prostatic hyperplasia(BPH) were treated with tamsulosin 0. 2mg and 0. 4mg daily respectively , and using terazosin 2mg daily for 30 patients as control. Tamsulosin and terazosin were effective and safe, in improving the patients’ symptoms and life quality, increasing urinary flow rate and decreasing residual urine. No significant differences were found in clinical efficacy between tamsulosin and terazosin, but the incidence of adverse events were much lower in tamsulosin group than in terazosin group, especially in terms fo cardiovascular system. Tamsulosin 0. 4mg daily produced greater improvements than the dose of 0. 2mg daily, and the incidence of side effects did not increase, so it could be used for the patients with severe symptoms. The study suggests that tamsulosin is an optimal selective alpha1A-adrenoceptor antagonist in the treatment of patients with symptomatic BPH.更多还原